{"id":"transderm-scop","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Dry mouth"},{"rate":"15-30","effect":"Drowsiness"},{"rate":"5-15","effect":"Blurred vision"},{"rate":"5-10","effect":"Dizziness"},{"rate":"common","effect":"Mydriasis (dilated pupils)"}]},"_chembl":{"chemblId":"CHEMBL569713","moleculeType":"Small molecule","molecularWeight":"303.36"},"_dailymed":{"setId":"b877a694-a1d0-4280-937a-a06820b12a88","title":"TRANSDERM SCOP (SCOPOLAMINE) PATCH, EXTENDED RELEASE [BAXTER HEALTHCARE CORPORATION]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Scopolamine is an anticholinergic agent that antagonizes muscarinic acetylcholine receptors in the central nervous system, particularly in the vomiting center and vestibular nuclei. The transdermal patch formulation provides sustained delivery of the drug, making it effective for motion sickness and postoperative nausea and vomiting (PONV) prevention. Its anticholinergic properties also produce mild sedation, which may contribute to its antiemetic effect.","oneSentence":"Scopolamine blocks muscarinic acetylcholine receptors to prevent nausea and vomiting by reducing vestibular and chemoreceptor trigger zone activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:57.332Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of motion sickness"},{"name":"Prevention of postoperative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT07267130","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2025-11-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":57},{"nctId":"NCT03616067","phase":"PHASE3","title":"Evaluation of the Efficacy of the Injection of Botulinum Toxin A vs Scopolamine Patches in the Treatment of Drooling in Children With Cerebral Palsy","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2022-04-27","conditions":"Cerebral Palsy","enrollment":23},{"nctId":"NCT05640232","phase":"PHASE3","title":"Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea","status":"RECRUITING","sponsor":"EMS","startDate":"2025-06-11","conditions":"Primary Dysmenorrhea","enrollment":238},{"nctId":"NCT05362487","phase":"","title":"Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2022-08-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":9},{"nctId":"NCT05165485","phase":"PHASE4","title":"Phase 4 COPD and Suboptimal Inspiratory Flow Rate","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2022-01-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":404},{"nctId":"NCT01152450","phase":"PHASE2","title":"A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-07","conditions":"Asthma","enrollment":94},{"nctId":"NCT06679465","phase":"PHASE4","title":"Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response","status":"NOT_YET_RECRUITING","sponsor":"University of Saskatchewan","startDate":"2025-01-01","conditions":"Asthma Bronchiale","enrollment":10},{"nctId":"NCT04672941","phase":"","title":"Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-02-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1396},{"nctId":"NCT05986591","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-08-17","conditions":"COPD","enrollment":335},{"nctId":"NCT00388882","phase":"PHASE4","title":"Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-10-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":327},{"nctId":"NCT02242266","phase":"PHASE2","title":"Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":121},{"nctId":"NCT00668772","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder in COPD","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT05169424","phase":"","title":"A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":9117},{"nctId":"NCT00662740","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":220},{"nctId":"NCT05911126","phase":"NA","title":"How to Reduce Pain in Patients Undergoing Office Hysteroscopy.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-06-13","conditions":"Pain","enrollment":180},{"nctId":"NCT05161156","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium Bromide Inhalation Powder","status":"COMPLETED","sponsor":"Phargentis SA","startDate":"2022-03-24","conditions":"COPD","enrollment":306},{"nctId":"NCT02812862","phase":"PHASE4","title":"Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD","status":"WITHDRAWN","sponsor":"RWTH Aachen University","startDate":"2016-08","conditions":"COPD","enrollment":""},{"nctId":"NCT04249310","phase":"","title":"Early Intervention Efficacy in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-03-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":6788},{"nctId":"NCT02864407","phase":"","title":"Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-12-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3223},{"nctId":"NCT03095456","phase":"PHASE3","title":"Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2017-03-27","conditions":"Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)","enrollment":207},{"nctId":"NCT04552847","phase":"PHASE2, PHASE3","title":"Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-10-07","conditions":"Neuroendocrine Tumors","enrollment":85},{"nctId":"NCT04926233","phase":"","title":"Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1371146},{"nctId":"NCT03979807","phase":"","title":"A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-06-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":11296},{"nctId":"NCT02203474","phase":"PHASE2","title":"A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT02467452","phase":"PHASE3","title":"Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1479},{"nctId":"NCT03158311","phase":"PHASE3","title":"Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-05","conditions":"Asthma","enrollment":1426},{"nctId":"NCT03084796","phase":"PHASE2","title":"A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":733},{"nctId":"NCT03137992","phase":"PHASE3","title":"Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2017-11-21","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":377},{"nctId":"NCT04011735","phase":"","title":"Re-usable Respimat® Soft MistTM Inhaler Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":262},{"nctId":"NCT00557180","phase":"","title":"Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2007-10","conditions":"Asthma, Obesity","enrollment":33},{"nctId":"NCT02845752","phase":"PHASE4","title":"The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-03-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":14},{"nctId":"NCT02541006","phase":"PHASE4","title":"Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2014-11","conditions":"COPD","enrollment":58},{"nctId":"NCT02988869","phase":"PHASE4","title":"Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2016-08","conditions":"COPD","enrollment":84},{"nctId":"NCT03395002","phase":"PHASE4","title":"Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-03-22","conditions":"COPD","enrollment":58},{"nctId":"NCT03240575","phase":"PHASE4","title":"The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-08-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":302},{"nctId":"NCT04272255","phase":"PHASE3","title":"Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness","status":"UNKNOWN","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-04-22","conditions":"Motion Sickness","enrollment":300},{"nctId":"NCT04219982","phase":"PHASE2, PHASE3","title":"DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness","status":"TERMINATED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2018-06-29","conditions":"Motion Sickness","enrollment":23},{"nctId":"NCT04184115","phase":"PHASE3","title":"Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness","status":"COMPLETED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-06-09","conditions":"Motion Sickness","enrollment":102},{"nctId":"NCT03188120","phase":"","title":"Specific Use-Result of Spiriva Respimat® in Asthmatics","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-07-04","conditions":"Asthma","enrollment":193},{"nctId":"NCT02853123","phase":"PHASE4","title":"Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-09-22","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":106},{"nctId":"NCT02566031","phase":"PHASE4","title":"A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-23","conditions":"COPD","enrollment":379},{"nctId":"NCT03055988","phase":"PHASE4","title":"Cardiovascular Function in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76},{"nctId":"NCT03118765","phase":"PHASE2","title":"Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2017-03-24","conditions":"Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)","enrollment":155},{"nctId":"NCT02059434","phase":"PHASE1","title":"Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Asthma","enrollment":55},{"nctId":"NCT02567214","phase":"PHASE4","title":"Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Laval University","startDate":"2016-06","conditions":"COPD","enrollment":50},{"nctId":"NCT02603393","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1053},{"nctId":"NCT02039050","phase":"PHASE4","title":"Evaluation of Long-Acting Muscarinic Antagonists in COPD","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2014-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":15},{"nctId":"NCT03745261","phase":"PHASE3","title":"Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2018-06-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":240},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT02573155","phase":"PHASE1","title":"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10","conditions":"Asthma (Part 1), COPD (Part 2)","enrollment":134},{"nctId":"NCT01662986","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT01663987","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT03499743","phase":"NA","title":"Celecoxib Versus Hyoscine Butyl-bromide in Reducing Pain Associated With IUD.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2018-04-20","conditions":"IUD Insertion Pain","enrollment":105},{"nctId":"NCT02172495","phase":"","title":"Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":4700},{"nctId":"NCT02683109","phase":"PHASE4","title":"Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-03-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":221},{"nctId":"NCT01937390","phase":"","title":"Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":645},{"nctId":"NCT00565266","phase":"PHASE3","title":"Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-05","conditions":"Asthma","enrollment":210},{"nctId":"NCT02275481","phase":"PHASE4","title":"A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":66},{"nctId":"NCT03029650","phase":"PHASE4","title":"Scopolamine Patch Pharmacokinetics in Healthy Adults","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2016-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT01426009","phase":"PHASE2","title":"Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study","status":"COMPLETED","sponsor":"Sunovion Respiratory Development Inc.","startDate":"2011-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":140},{"nctId":"NCT02276222","phase":"PHASE3","title":"A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD","status":"COMPLETED","sponsor":"Sunovion Respiratory Development Inc.","startDate":"2014-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1087},{"nctId":"NCT00122434","phase":"PHASE2","title":"Dose Finding Study in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":389},{"nctId":"NCT01566773","phase":"PHASE2","title":"PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":140},{"nctId":"NCT01381406","phase":"","title":"Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3333},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226},{"nctId":"NCT03169504","phase":"PHASE3","title":"Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2017-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":150},{"nctId":"NCT01387178","phase":"","title":"Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22223},{"nctId":"NCT01085045","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":118},{"nctId":"NCT02347072","phase":"PHASE3","title":"24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-02-01","conditions":"COPD","enrollment":80},{"nctId":"NCT02331940","phase":"NA","title":"Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients","status":"COMPLETED","sponsor":"University of Crete","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":200},{"nctId":"NCT01727024","phase":"PHASE4","title":"Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":140},{"nctId":"NCT02085161","phase":"PHASE3","title":"To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":304},{"nctId":"NCT00868231","phase":"PHASE2","title":"Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":30},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT01525615","phase":"PHASE3","title":"A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":404},{"nctId":"NCT01634139","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":403},{"nctId":"NCT01959516","phase":"PHASE4","title":"Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02","conditions":"COPD","enrollment":124},{"nctId":"NCT01929044","phase":"PHASE3","title":"Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-08","conditions":"Intestinal Diseases","enrollment":299},{"nctId":"NCT01969721","phase":"PHASE3","title":"Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":229},{"nctId":"NCT01634152","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":401},{"nctId":"NCT02231177","phase":"PHASE1","title":"Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":47},{"nctId":"NCT01533935","phase":"PHASE3","title":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":291},{"nctId":"NCT01533922","phase":"PHASE3","title":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":295},{"nctId":"NCT00720499","phase":"PHASE2","title":"Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":141},{"nctId":"NCT00696020","phase":"PHASE2","title":"Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":360},{"nctId":"NCT01431274","phase":"PHASE3","title":"Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2624},{"nctId":"NCT01559116","phase":"PHASE3","title":"Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":219},{"nctId":"NCT02030535","phase":"PHASE2","title":"Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":53},{"nctId":"NCT01431287","phase":"PHASE3","title":"Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2539},{"nctId":"NCT01634113","phase":"PHASE2","title":"Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":102},{"nctId":"NCT01383499","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-08","conditions":"Asthma","enrollment":101},{"nctId":"NCT01316380","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-03","conditions":"Asthma","enrollment":465},{"nctId":"NCT02257463","phase":"NA","title":"Effect of Inspiratory Muscle Training on Exercise Performance and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":60},{"nctId":"NCT01397890","phase":"PHASE4","title":"Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":793},{"nctId":"NCT01922271","phase":"PHASE4","title":"Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":152},{"nctId":"NCT01696058","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1137},{"nctId":"NCT01277523","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-01","conditions":"Asthma","enrollment":392},{"nctId":"NCT02263976","phase":"PHASE1","title":"Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-08","conditions":"Healthy","enrollment":101},{"nctId":"NCT02261077","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-05","conditions":"Healthy","enrollment":60},{"nctId":"NCT02259946","phase":"PHASE1","title":"Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Healthy","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Transderm Scop®","genericName":"Transderm Scop®","companyName":"University of Iowa","companyId":"university-of-iowa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Scopolamine blocks muscarinic acetylcholine receptors to prevent nausea and vomiting by reducing vestibular and chemoreceptor trigger zone activity. Used for Prevention of motion sickness, Prevention of postoperative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}